KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

T-cell therapy has shown remarkable clinical efficacy in haematological malignancies, currently representing a well ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Glioblastoma has been deadly and hard to treat, but researchers say they’ve made progress with bivalent CAR T-cell therapy ...

Taking inspiration from the CAR T-cell technology used to provide personalized cancer treatments, researchers have conducted ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain ...

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy ...

This article explores the current landscape and future potential of cell therapies, including CAR T-cell and stem cell-based ...

AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK ...